Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-1999 | 03-1999 | 12-1998 | 09-1998 | 06-1998 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 690 | 1,650 | -13,150 | -12,660 | -8,980 |
| Depreciation Amortization | 510 | 250 | 1,190 | 970 | 670 |
| Other Working Capital | -5,100 | -3,280 | 4,840 | 5,190 | 2,940 |
| Other Operating Activity | -1,890 | -3,270 | -900 | -1,700 | 1,120 |
| Operating Cash Flow | $-5,790 | $-4,650 | $-8,020 | $-8,200 | $-4,250 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 3,490 | 3,570 | -100 | -100 | -90 |
| Net Acquisitions | 550 | 0 | 2,000 | 2,000 | 0 |
| Other Investing Activity | 0 | 0 | 0 | -10 | 0 |
| Investing Cash Flow | $4,040 | $3,570 | $1,900 | $1,890 | $-90 |
| Cash Flows From Financing Activities | |||||
| Dividend Paid | 0 | 0 | -10 | 0 | 0 |
| Other Financing Activity | 4,060 | 4,130 | 1,740 | 1,930 | -30 |
| Financing Cash Flow | $4,060 | $4,130 | $1,730 | $1,930 | $-30 |
| Beginning Cash Position | 3,010 | 3,010 | 7,400 | 7,400 | 7,400 |
| End Cash Position | 5,330 | 6,070 | 3,010 | 3,020 | 3,010 |
| Net Cash Flow | $2,310 | $3,050 | $-4,380 | $-4,370 | $-4,380 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,790 | -4,650 | -8,020 | -8,200 | -4,250 |
| Free Cash Flow | -5,790 | -4,650 | -8,020 | -8,200 | -4,250 |